With strong three-month performance and significant upside potential, CytomX Therapeutics, Inc. (NASDAQ:CTMX) secures a spot on our list of the 12 hot penny stocks to invest in right now.
The Fly reported on November 11, 2025, that CytomX Therapeutics, Inc.’s price target was raised from $5 to $10 by H.C. Wainwright’s Mitchell Kapoor. Reiterating a “Buy” rating, the analyst highlighted strong demand for the CX-2051 Phase 1 program. With Phase 1 study enrollment projected to reach approximately 100 patients by Q1 2026, the program’s data package is expected to strengthen, supporting a potential approval pathway.
Meanwhile, CytomX Therapeutics, Inc. reported its Q3 2025 results on November 6, 2025. The quarter saw a reduction in revenue to $6 million from $33.4 million in Q3 2024. The revenue decline reflected the completion of certain collaboration obligations. However, operating expenses, which fell to $21.7 million, reflected the company’s continued operating discipline.
The quarter also marked significant pipeline progress, including a robust CX-2051 Phase 1 expansion and preparations for a data update in Q1 2026. Management expressed confidence while emphasizing ongoing CX-801 development, including upcoming biomarker data at SITC 2025 Annual Meeting and continued dose escalation in combination with KEYTRUDA. CytomX Therapeutics, Inc. closed the quarter with $143.6 million in cash balances, supporting operations until Q2 2027.
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, develops conditionally activated, tumor-localized biologics using its PROBODY platform.
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.
